Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Eden Biodesign and the University of Birmingham develop therapeutic candidate for the treatment of autoimmune diseases

02 Aug 2007 - Eden Biodesign Ltd announced today that it has been selected by the University of Birmingham to develop and produce vOX2:Fc, a novel therapeutic candidate for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The novel drug candidate is investigated by Dr David Blackbourn and his research team and has already attracted interest from a number of biotech and pharmaceutical companies.
 
Dr David Blackbourn commented: "Working with Eden Biodesign will allow us to advance our understanding of the therapeutic potential of this drug candidate; clinical applications for this novel therapy could range from autoimmune diseases such as rheumatoid arthritis to asthma and allergy. We are delighted to have Eden Biodesign contribute to the vOX2 programme at the state of the art facility in Liverpool."